HCA Healthcare, Inc. (HCA) Up 7.2% — Should I Upgrade This From Watchlist to Buy?
HCA Healthcare, Inc. (HCA) is pushing sharply higher on Wednesday, last trading at $496.23 on the NYSE — a $33.37 gain over the prior close of $462.86. The advance lifts the stock roughly 40.2% above its 52-week low of $353.99 and brings it within about 10.8% of its 52-week high of $556.52, a level set on March 12, 2026. With the shares now trading in the upper portion of their $353.99 to $556.52 annual range, the path back toward that March peak looks considerably shorter than it did a day ago.
Volume stands at approximately 1.01 million shares with the session still underway, compared with a 90-day average of roughly 1.43 million. Intraday turnover has already reached about 70% of a typical full day, so the gain is drawing real participation well before the close.
Why HCA Healthcare, Inc. Price is Moving Higher
The driver is political, and it is lifting the entire Health Care sector. Reuters reported on November 4, 2026, that Democrats swept both the House and the Senate. Managed care and hospital stocks rallied together in response. Centene (CNC) gained about 8% earlier today, Molina (MOH) rose 6%, and Elevance (ELV) added 3%. Hospital operators HCA, Tenet (THC), and Universal Health Services (UHS) climbed 6% to 8% as a group. The buying reached beyond providers as well. Medtronic plc (MDT) is up 5.92% today, and Labcorp Holdings Inc. (LH) is up 2.54%. The breadth of the move shows investors repricing policy risk across the group, and HCA's 7.21% gain sits squarely within the hospital cohort's range.
The policy logic favors hospital operators directly. Bernstein said the election result could delay parts of the 2025 One Big Beautiful Bill Act, the provisions expected to reduce Medicaid enrollment and constrain state healthcare payments. Bernstein also said the outcome improves the prospects for extending marketplace subsidies. For HCA, that combination points to fewer patients losing coverage and less pressure on state-directed hospital payments. Both outcomes bear directly on payer mix and uncompensated care. JPMorgan noted that major policy changes remain uncertain. Even so, the market is assigning meaningful odds to a gentler reimbursement environment than it had been pricing in.
The rally also builds on a strong earnings report. On October 27, HCA posted Q3 adjusted EPS of $7.22, well ahead of the $6.65 consensus. Revenue reached $19.85 billion against expectations of $19.33 billion. Revenue rose 3.6% year over year, while net income slipped 3.9% to $1.579 billion. Management said 2026 results should land in the upper half of its existing guidance. Its preliminary 2027 view calls for earnings generally consistent with 2026. That flat outlook now looks conservative if the policy backdrop turns less hostile, and it gives HCA room to beat expectations next year.
What is the HCA Healthcare, Inc. Rating - Should I Buy?
Weiss Ratings assigns HCA a B- rating. The rating was upgraded on 10/7/2026. Current recommendation is Buy. The upgrade came weeks before Q3 beat and today's policy-driven rally, so the Weiss framework had already registered improving fundamentals before the market caught up.
The case rests on HCA's operating engine. The company is rated Excellent on both the Growth Index and the Efficiency Index. Its 8.60% profit margin stands out for a hospital operator, an industry where labor, supplies, and uncompensated care routinely compress margins to thin levels. The same scale and cost discipline support trailing EPS of $30.18 and a quarter in which adjusted earnings cleared consensus by $0.57. Revenue growth of 3.59% is steady rather than spectacular. The Growth Index rating reflects a company converting modest top-line gains into strong per-share earnings, not one that depends on volume surges. The Good rating on the Total Return Index fits that profile. Holders who bought near the $353.99 low have been well rewarded, and a forward P/E of 15.34 leaves room for further gains rather than signaling a stretched valuation.
The picture becomes more measured on the Solvency, Volatility, and Dividend indices, each rated Fair. The Fair Solvency Index rating reflects the capital intensity of running a national hospital network. Facilities, equipment, and acquisitions require steady investment that keeps the balance sheet working hard. Today's 7.21% jump shows why the Volatility Index is not rated higher. HCA's share price remains highly sensitive to Washington, and election results and Medicaid policy can swing the stock by several percentage points in a single session. The Fair Dividend Index rating follows from a 0.66% yield. Shareholder returns at HCA come primarily through earnings growth and price appreciation rather than income.
Within the Health Care sector, HCA is on par with Medtronic plc (MDT, B-). It trails McKesson Corporation (MCK, B), Cardinal Health, Inc. (CAH, B+), and Labcorp Holdings Inc. (LH, A-). All of these names sit in Buy territory, and HCA brings the most direct exposure to a policy shift that favors hospital volumes and reimbursement.
About HCA Healthcare, Inc.
HCA Healthcare, Inc. (HCA) is a Health Care company operating within the Health Care Equipment and Services industry. Through its subsidiaries, it is one of the largest providers of health care services in the United States. Founded in 1968 and headquartered in Nashville, Tennessee, the company was formerly known as HCA Holdings, Inc. It owns, manages, and operates a network that spans general and acute care hospitals, ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, and walk-in clinics.
Its hospitals deliver medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic services, and emergency services. HCA pairs that inpatient base with a large outpatient footprint covering outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. Beyond the hospital campus, the company operates diagnostic and imaging centers, radiation and oncology therapy centers, and rehabilitation and physical therapy centers. Its network also includes physician practices, home health agencies, hospices, outpatient physical therapy providers, and home and community-based services providers.
That breadth is HCA's core competitive advantage. By owning care settings across the full continuum, from emergency and acute care through outpatient procedures, post-acute recovery, and home-based services, HCA captures patients at multiple points in their care. It can also steer volume toward its most efficient sites. Its scale gives it leverage with commercial payers and suppliers, and its dense regional market positions are difficult for smaller operators to replicate.
Investor Outlook
HCA Healthcare, Inc. (HCA) carries a Weiss Rating of B- (Buy). The combination of a fresh upgrade, a clear Q3 earnings beat, and a potentially friendlier policy backdrop makes it a name with real upside momentum. Investors should watch how Washington handles the Medicaid provisions of the One Big Beautiful Bill Act and the marketplace subsidy extension. They should also watch whether HCA's conservative 2027 earnings outlook gets revised higher as that picture clarifies. See full rankings of all B- rated Health Care stocks inside the Weiss Stock Screener.
--